SCHEMBL22320773

SCHEMBL22320773

N#CC(=NNc1ccccc1)C(=O)c1noc2ccccc12

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAPGEF3 O95398 12/20 0.80
HIF1A Q16665 2/20 0.53
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 2/20 0.49
ALOX12 P18054 1/20 0.49
NPY1R P25929 1/20 0.49
NPY2R P49146 1/20 0.49
ALB P02768 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22340287 1.00 RAPGEF3 (0.80) RAPGEF3HIF1AMAPTLMNAHTT
SCHEMBL20523713 0.89 RAPGEF3 (1.00) RAPGEF3HIF1AMAPTLMNAHTT
SCHEMBL20523709 0.87 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL20523743 0.85 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL22320774 0.84 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL22320771 0.83 RAPGEF3 (1.00) RAPGEF3MAPTLMNAHTTSMN1; SMN2
SCHEMBL20523694 0.81 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL20523676 0.81 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL20523680 0.81 RAPGEF3 (1.00) RAPGEF3RAPGEF4
SCHEMBL22340288 0.77 RAPGEF3 (0.56) RAPGEF3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 UNIV TEXAS (US) 2023-05-18 US disclosed
EP-4121411-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-01-25 EP disclosed
WO-2021188728-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-23 WO disclosed
US-11124489-B2 EPAC antagonists BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-21 US disclosed
US-20200255388-A1 EPAC ANTAGONISTS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 CREB1, RAPGEF4, ATF4 RAPGEF3 4/4885HIF1A 1215/4885MAPT 4881/4885
US-20200255388-A1 EPAC ANTAGONISTS EPAS1, GPR139, CRACR2A RAPGEF3 5/4885HIF1A 1159/4885MAPT 4650/4885
US-11124489-B2 EPAC antagonists EPAS1, GPR139, CRACR2A RAPGEF3 5/4885HIF1A 1159/4885MAPT 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.